about
New-Onset Refractory Status Epilepticus: More Investigations, More QuestionsSusac-like syndrome in a chronic cocaine abuser: could levamisole play a role?Genetic variants are major determinants of CSF antibody levels in multiple sclerosis.IL-22, GM-CSF and IL-17 in peripheral CD4+ T cell subpopulations during multiple sclerosis relapses and remission. Impact of corticosteroid therapy.Voxel-based lesion-symptom mapping of stroke lesions underlying somatosensory deficits.Early disturbances in multimodal evoked potentials as a prognostic factor for long-term disability in relapsing-remitting multiple sclerosis patients.Decrease of blood anti-α1,3 Galactose Abs levels in multiple sclerosis (MS) and clinically isolated syndrome (CIS) patients.Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice.Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.Corticosteroids in the management of acute multiple sclerosis exacerbations.Contribution of different relapse phenotypes to disability in multiple sclerosis.Regulation of Treg-associated CD39 in multiple sclerosis and effects of corticotherapy during relapse.Visual evoked potentials monitoring in a case of transient post-operative visual loss.Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.[Physiotherapy and neurogenic lower urinary tract dysfunction in multiple sclerosis patients: a randomized controlled trial].Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patientsSafety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program.Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.Fatigue and physical fitness of mildly disabled persons with multiple sclerosis: a cross-sectional study.Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.Early relapse with tumefactive MS lesion upon initiation of fingolimod therapy.Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis.Herpes simplex encephalitis relapse associated with positive N-methyl-D-aspartate receptor antibodies.Defining reliable disability outcomes in multiple sclerosis.Risk of relapse phenotype recurrence in multiple sclerosis.Cramp-fasciculation syndrome associated with monofocal motor neuropathy.Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisAnti-inflammatory disease modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort studyTimed up-and-go and 2-minute walk test in patients with multiple sclerosis with mild disability: reliability, responsiveness and link with perceived fatigueInternational consensus on quality standards for brain health-focused care in multiple sclerosisWhich treatment strategies for polyrefractory Neuro-Behçet disease?Correction to: Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensusA Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosisAuto-immune hepatitis in a patient with multiple sclerosis treated with alemtuzumabCSF microRNAs discriminate MS activity and share similarity to other neuroinflammatory disordersEffects of Fampridine in People with Multiple Sclerosis: A Systematic Review and Meta-analysisIncidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study
P50
Q26315239-17B0750E-49DA-4C68-8D62-35F80610539EQ35210133-34A6920A-1DA3-45F1-A80D-9CB80C90C7D3Q35533986-D11DF64F-4E0F-4CD7-AFDC-F01D5BA6A44FQ36310557-01C942C4-589C-4B78-BB8A-C33165849502Q36493468-BA0DA4D9-41F1-436E-9440-1765586F67CAQ38754046-4FDA8BE5-B27F-4F8A-92EF-3900AC94047CQ38784879-48063E5A-1685-4D58-8D2C-AB6DC6B32D79Q38791015-426017C6-BC43-4698-97CD-8E5C948C41B4Q38850911-5B1DF8D0-7A53-4C66-9BE6-63C89FB2B275Q38956663-4DC9A6BE-F7E7-43AD-8998-D80C558A44E3Q39229363-6C154739-A619-4ECA-933D-246B422E0A98Q40724148-92E89C94-5B5F-4E60-93A5-7277B018633CQ41463764-6EF52C85-6347-4F68-AB42-2DF218A82361Q41675560-198BB35E-1939-44B2-BEAB-38C6C8F4F5C3Q41721827-FD3708DA-A453-4B6D-A0A2-D17151FC6743Q41741865-D68279DC-3A26-455A-BAF7-D33FE8C684E3Q42012792-FD6E4E92-3FEB-4C96-9E14-3C70CEE5E070Q42665193-9BEDD313-AFF8-4A79-9604-4C5C4FBB0B49Q47639943-2FCCFF65-90C0-48BB-B802-BDC11039DE4AQ47842800-89873477-61EB-4765-9CC8-AB2415DB12EFQ48144826-396DC611-103F-4DE1-9631-C3535AAA0722Q48174040-816F05B0-A6C9-47D7-924A-0FC28D1D9675Q48607199-EFC193A0-CFEC-4F49-9563-ACFC9C4C1FA9Q48922719-85DB53BD-3815-434A-B92F-AE41B25E24A7Q49164654-AD54C8E7-8A53-4712-A26E-380AAB4BF11DQ49948789-5BCDB900-8A6C-456B-BCFA-D33216899C9EQ52149517-853FBEBC-45C5-4654-A053-EF87FB17C654Q53090722-2F2AE1D3-AFAA-4A5A-82FE-2E38082C01ACQ53763833-F5D34D78-374D-4C60-8F14-B0CBE5350550Q56348057-090C0826-77E7-4F75-815D-275EBE577CA8Q57288599-1CBC35B7-7E1C-4694-B2DC-A2AAEBE4A680Q57483642-3C1464A2-50B9-4149-9622-4780AC0C3140Q58083652-3F2320C3-37D5-4E35-91E0-185501A00EB5Q58568967-E99FD2A7-C4E1-49AA-BF70-D3AE90AE9E0AQ87944994-B32144C3-E93A-4144-AD48-37A3ECCCEA8FQ88047177-14E04432-5DFE-4438-BB67-FD17DD896171Q88527966-E60C02CF-BBCF-4C8C-A7BB-F1FCF7D19506Q89601045-E532F0C8-6615-4F24-BDCB-5FA9DB379245Q90708213-6B8326E5-35C9-47A6-AC1D-DA086BD8ACEAQ90957112-FDB4AD01-6FBA-4A41-B6FA-0F41A102BEE3
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Vincent van Pesch
@ast
Vincent van Pesch
@en
Vincent van Pesch
@es
Vincent van Pesch
@nl
Vincent van Pesch
@sl
type
label
Vincent van Pesch
@ast
Vincent van Pesch
@en
Vincent van Pesch
@es
Vincent van Pesch
@nl
Vincent van Pesch
@sl
prefLabel
Vincent van Pesch
@ast
Vincent van Pesch
@en
Vincent van Pesch
@es
Vincent van Pesch
@nl
Vincent van Pesch
@sl
P106
P21
P2798
P31
P496
0000-0003-2885-9004
P569
2000-01-01T00:00:00Z